Brief: Newron to re-submit US NDA for Xadago

Newron Pharmaceuticals SpA

26/07/2016 06:01

July 26 (Reuters) - Newron Pharmaceuticals SpA  NWRN.S : 
    * Newron prior regulatory filing for xadago (safinamide) in 
the US 
    * Newron to re-submit US NDA for Xadago 
    * FDA does not require further studies to misuse or 
dependence 
    * Newron and the FDA agreed on the contents of the nda 
re-submission which newron expects to complete by November of 
this year 
 
Source text for Eikon:  ID:nTENncn3oa  
Further company coverage:  NWRN.S  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 722 0920;))